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Abstract
Objectives—To measure rates and predictors of virologic failure and switch to second-line ART
in South Africa.
Design—Observational cohort study
Methods—We included ART-naïve adult patients initiated on public-sector ART (Jan 2000–July
2008) at five sites in South Africa who completed ≥6 months of follow-up. We estimated
cumulative risk of virologic failure (viral load ≥400 copies/ml with confirmation above varying
thresholds) and switching to second-line ART.
Results—19,645 patients (29,935 person-years) had a median of 1.3 years of study follow-up
(1.8 years on ART) and a median CD4 count of 96 (IQR:40–159) cells/μl at ART initiation. 9.9%
(4.5/100 person-years) failed ART in median 16 (IQR:12–23) months since ART initiation, with
median 2.9 (IQR:1.8–5.0) months between first elevated and confirmatory viral loads. By survival
analysis, using a confirmatory threshold of 400 copies/ml, 16.9% (95%CI:15.4–18.6%) failed by
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five years on ART, but only 7.8% (95%CI:6.6%-9.3%) using a threshold of 10,000. CD4 <25 vs.
100–199 (adjusted HR:1.57;95%CI 1.35–1.83), ART initiation viral load ≥1,000,000 vs. <10,000,
(1.32;0.91–1.93) and 2+ gaps in care vs. 0 (95%CI:6.61; 4.52–9.68) were predictive of failure.
Overall 10.1% (95%CI:9.0%-11.4%) switched to second-line by five years on ART. Lower CD4
at failure and higher rate of CD4 decline were predictive of switch (decline 100% to 51% vs. 25%
to −25%, adjusted HR:1.96;95%CI:1.35–2.85).
Conclusions—In resource-limited settings with viral load monitoring, virologic failure rates are
highly sensitive to thresholds for confirmation. Despite clear guidelines there is considerable
variability in switching failing patients, partially in response to immunologic status and post-
failure evolution.
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INTRODUCTION
As the global scale-up of antiretroviral therapy (ART) has reached nearly five million
people,1 a growing body of evidence from large observational cohorts has demonstrated
positive clinical, immunologic and virologic outcomes being achieved throughout sub-
Saharan Africa.2–7 Even though large numbers of new patients are still starting treatment in
resource-limited settings, focus is shifting from the short-term stresses of treatment initiation
to the long-term problems of managing a lifelong chronic disease. A critical part of this shift
is an emphasis on managing the growing number of public-sector patients who already have
failed or will soon fail first-line therapy.8–13
While recent estimates suggest only 2% of those currently on ART are on a second-line
regimen,14 a far greater number are likely to be failing virologically but have not switched
from first-line therapy: WHO estimates that 500,000 to 800,000 patients required switching
to second-line regimens by 2010.15 As ART scale-up continues and the average duration on
ART increases, both the absolute number and relative proportion of patients needing second-
line therapy continues to grow. It has previously been estimated in South Africa that by 5-
years on ART 14% of patients fail virologically.2
Poor access to HIV-1 RNA viral load testing is a key challenge facing many national
programs 12,16 and therefore reliance on clinical and immunologic means of determining
when to switch, which have poor predictive ability for virologic failure, is problematic.17–22
There is increasing pressure to improve access to viral load testing in high burden settings,
and we recently reported improved outcomes in programmes in Southern Africa which
utilize routine viral load testing.12 South Africa is one of the few high-burden settings to
follow the public health approach to ART service delivery, with access to routine viral load
monitoring and a standardized approach to confirming virologic failure. In settings with
access to viral load testing, WHO recommends switching therapy when a patient has a
persistent viral load above 5,000 viral copies/ml.1 The performance of this guidance at a
national level, and the programme-level impact of different thresholds for determining
virologic failure have not previously been described.
Individual cohorts have reported on durability of first-line regimens, associations with
confirmed virologic failure, and delays in switching to second-line, but there is limited
understanding of factors predicting switch after virologic failure, and how consistent
practice is with respect to switching failing patients to second-line therapy.12 We examined
the impact of the definition of virologic failure on failure rates, quantified rates of virologic
failure and switch to second-line ART, and studied predictors of each in a combined cohort
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of nearly 20,000 patients initiating ART throughout South Africa. We also explored
variability in switching rates by treatment program.
METHODS
Study Design and Population
The data for this analysis come from the IeDEA-SA collaboration
(http://www.iedea-sa.org/), a collaboration of HIV treatment programmes in Southern Africa
combining prospectively collected clinical treatment data from 25 programmes.23 At the
time of data transfer, participating sites represented nearly 10% of all South African adult
public-sector patients initiating ART.24 We included data from five programs, operating
throughout the country, with adequate viral load data. All clinics followed the 2004 South
African National Treatment Guidelines for public-sector ART provision.25 While these
guidelines have recently been revised,26 during the study period patients whose CD4 cell
count declined to below 200 cells/ml3 or who were diagnosed with a WHO Stage IV
condition (excluding extra-pulmonary tuberculosis) were eligible for ART. Standard first-
line regimens comprised stavudine (d4T) with lamivudine (3TC) and either efavirenz (EFV)
or nevirapine (NVP). Zidovudine (AZT) was available for specific indications. Once on
ART, guidelines provided for 6-monthly viral load and CD4 count monitoring. In four of the
five sites viral load testing was done by the National Health Laboratory Service (NucliSens
EasyQ HIV-1 assay; bioMérieux, Boxtel, The Netherlands), while in Gugulethu a private
laboratory provided the viral load testing (Bayer HIV-1 RNA 3.0 assay, Leverkusen,
Germany). Virological failure was defined as a two consecutive viral loads above 400
copies/mL, with the second value >5000 copies/mL despite stepped-up adherence
interventions. The recommended second-line regimen was AZT, didanosine (ddi) and
lopinavir-ritonavir (LPVr). There was some variation in the application of these guidelines,
largely because some sites initiated ART prior to formalization of national guidelines. This
included using AZT over d4T, the timing of the first monitoring viral load, the frequency of
monitoring and the sequential thresholds used to designate confirmed virologic failure
(Table 1). Sites nevertheless closely followed a uniform national programme with respect to
ART eligibility, patient preparation, regimens, monitoring frequency and failure
definitions,27 facilitating this combined analysis.
Analytic Strategy
Eligible patients were ART naïve adults aged ≥16 initiated on a standard first-line ART
regimen at one of the five sites between Jan 2000 and July 2008, and who completed ≥6
months of follow-up after ART initiation. We conducted three analyses: of 1) time to
virologic treatment failure in which we varied the failure definition; 2) the rate and
predictors of treatment failure using a common virologic failure definition; and 3) time to
and predictors of switching to second-line ART among those failing first-line. For the time-
to-switch analysis we included only patients in care for six-months after documented
virologic failure. Patients who were never virologically suppressed were included in the
main analyses, but were excluded in a sensitivity analysis. Viral load testing completeness at
2 years duration on ART was estimated for each cohort for all patients followed up for at
least 27 months based on viral loads taken between 21 and 27 months on ART.
For analysis 1, we defined treatment failure as a detectable viral load (≥400 copies/ml) after
6 months on first-line ART followed by a second consecutive viral load above a threshold
(which varied) separated by between 2 weeks and 1 year without suppression during that
time. We varied the threshold for the second elevated value (≥400, ≥1000, ≥5000, ≥10,000
copies/mL). Patients who died after a first elevated viral load (N=79) with no further
elevated viral load were not considered failures. Because some patients who were likely
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virologic failures died or left care before receiving a confirmatory viral load, in sensitivity
analyses we analyzed rates of confirmed failure or death after initial viral load elevation to
account for missed failures in patients who died. For analysis 2 we used a threshold of
≥1000 (referred to as the “common failure definition”), because no cohort had a protocol
requiring switching below this threshold, which is now used in the South African national
ART programme.28 Analysis 3 was limited to patients meeting their clinic’s failure
definition (see Table 1), because sites typically would not switch patients who had not met
their definition. We defined switching to second-line ART as initiating a PI with a change in
at least one nucleoside reverse transcriptase inhibitor (NRTI), ≥6-months after starting first-
line therapy.
We defined treatment gaps as the number of days between the end date of all drugs in one
prescribed regimen and the start date of the next regimen. We defined CD4 count at ART
initiation as the last measure 12 months before through 14 days after initiation (87% of
patients had such a measure). We defined viral load at ART initiation as the last viral load
measure 6 months before through 3 days after ART initiation. For predictors of switching,
CD4 count and viral load at failure were defined as the temporally last measures 3 months
before through 2 weeks after the second detectable failing viral load. Because we
hypothesized clinicians would prioritize switching failing patients with low or dropping
CD4 counts, we include time updated “current” CD4 count after failure and CD4 decline as
predictors in multivariable models. For missing current CD4 counts, we carried forward the
last measure up to 9 months.
For failure analyses, person-time accrued from six months after initiating ART until the
earliest of death, loss to follow-up (LTFU), five years on ART, administrative censoring
(which varied by cohort but at latest was Jan 2009), or treatment failure (date of the second
elevated viral load). For switching analyses, person-time accrued from treatment failure until
the earliest of death, LTFU, administrative censoring, or switch. LTFU was determined to
have occurred at the last recorded visit and was defined based on each of the individual
sites’ definitions.
Statistical Methods
We derived Kaplan-Meier estimates of cumulative failure probabilities using the differing
failure definitions and stratified by predictors of failure. We estimated hazard ratios (HR) for
associations of patient characteristics with both virologic treatment failure and switch to
second-line ART using Cox proportional hazards regression. In addition to age and sex, we
included variables with a univariate p-value <0.2 in multivariable models. For failure
models we included cohort, ART initiation year, NNRTI in first-line ART (EFV/NVP), TB
treatment (Yes/No/Missing), WHO stage (I/II, III/IV, missing), CD4 count and viral load at
ART initiation and treatment interruptions of 7 days or more. For switch models we
included cohort, year of failure, years on ART at failure, current CD4 count, % change in
CD4 count from failure, and viral load at failure. As a sensitivity analysis, missing baseline
values were also imputed using fully conditional modeling by means of a chained equations
approach,29 with estimation results combined by Rubin’s rules.30
Ethics
Approval for analyses was given by the Universities of Cape Town, Bern and Boston
University. All sites had ethical approval to transfer anonymized data to the IeDEA data
center.
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RESULTS
Details of the five public-sector treatment sites in South Africa are given in Table 1. While
some patients initiated treatment as early as 1999, the majority initiated treatment since the
public-sector ART rollout in South Africa began in April 2004. Viral load testing
completeness at two years on ART ranged from 71% to 85%.
Cohort description
Of 23,465 adults completing 6 months of ART, 3,820 were excluded because they initiated a
nonstandard first-line regimen or their first-line regimen could not be determined. The
19,645 eligible patients were followed for 29,935 person-years (py) (median (range across
sites) 1.3 years (1.1–1.4) in the study and 1.8 years on ART). Excluded patients had similar
age, gender, cohort, TB treatment at ART initiation to eligible patients, but were more likely
to have initiated ART before 2004 (19% vs. 5%), be WHO Stage I/II (47% vs. 38%) and
have CD4 count >350 at ART initiation (27% vs. 1%).
Two programs accounted for 73% of all patients (Table 2). The majority of patients were
female (66%), initiated ART after 2005 (>51%), and initiated d4T-3TC-EFV (68%) or
d4T-3TC-NVP (21%). Advanced immunosuppression was common at ART initiation: 63%
of patients were WHO Stage III/IV, 30% had a CD4 count <50 and 36% were on
tuberculosis treatment. Median CD4 count at ART initiation was 93 (IQR:39–155) cells/μl.
Of 19,456 patients with known outcome 79% were alive and in care, 4.7% died, 9.4% were
lost to follow-up and 6.9% transferred.
Of the 19,645 patients, 17,272 (88%) achieved virologic suppression on first-line ART and
1348 (9.9%, 4.5/100 person-years) met the common failure definition (threshold ≥1000).
The median time from ART initiation until treatment failure among those who failed was 16
months (IQR:12–23), while the median time between the first and second detectable viral
loads was 2.7 months (IQR:1.6–4.7).
First-line Failure by Viral Load Threshold
Figure 1 shows cumulative probabilities of virologic treatment failure, using different
thresholds for confirmation in a Kaplan-Meier survival analysis. Between 6 months and five
years on ART, using our most sensitive confirmatory threshold (≥400 copies/ml), 16.9%
(95%CI:15.4–18.6%) of patients failed. The proportion failing was similar when increasing
this threshold to 1000 copies/ml, but was substantially less using thresholds of 5000 (10.0%;
95%CI:8.8%-11.2%) or 10,000 copies/ml (7.8%; 95%CI:6.6%- 9.3%, or 2.2 times less
likely to meet the definition compared to a threshold of 400 copies/ml). This last estimate
should be interpreted with caution, because no cohort used a threshold of 10,000 copies/ml
and so some patients failing at lower thresholds will have switched before reaching a
threshold of 10,000. When we limited the analysis for each threshold to only those cohorts
which in practice defined failure as greater than or equal to the threshold examined and
exclude the 10,000 group, results changed little (failure was 1.5 times greater comparing a
threshold of 400 to a threshold of 5000). In sensitivity analyses including deaths following a
single elevated viral load as failures, cumulative failure probability at 5 years on ART
ranged from 16.7–24.7% depending on the definition used.
Predictors of First-line Treatment Failure
Table 3 shows associations of patient characteristics with treatment failure, using the
common definition. In multivariable models (Table 3), age (per 10 year increase aHR:0.73;
95%CI:0.68–0.79), NVP use (aHR:1.52; 95%CI:1.34–1.73) and treatment provider were
associated with failure. The association between NVP use and failure remained when
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modeling this separately for men and women (aHR:1.70, 95%CI:1.30–2.21; 1.33, 1.13–
1.56). One cohort had a substantially lower failure rate compared to the others. A CD4 count
<25 at ART initiation cells/μl was associated with a 60% increased risk of failure compared
with those 100–199 cells/μl (aHR:1.60; 95%CI:1.37–1.87). While gaps in treatment of 7
days or more were uncommon (N=912, 4.6% of patients), two or more gaps was associated
with a 7-fold increased risk of failure (aHR:7.25; 95%CI:4.95–10.6) and one gap associated
with a 2-fold increased risk (aHR:2.46; 95%CI:2.11–2.87). Results were very similar when
using multiple imputation for missing data and when limited to patients who initially
achieved viral suppression. Results were also similar for the outcome of failure or death
except for an attenuation in the association with nevirapine in the initial regimen, the
increased risk associated with 2 or more gaps in care was reduced (HR 2.74; 95%CI:2.19–
3.45) and a stronger association between later year of ART initiation and reduced failure/
death was observed (data not shown).
Switching to Second-line
Among the 1348 patients meeting the common failure definition, 62% (833/1348) switched
to second-line ART. Overall 10.1% of the cohort were switched (9.0%-11.4%) to second-
line between six months and five years on ART (Figure 1). Of those who completed at least
six additional months of follow-up, 664 (74%) switched at some point after failure. Those
who switched did so a median of 4.6 months after failure (IQR:2.1–8.7). The majority (81%)
were switched to the government recommended regimen of AZT-ddi-LPVr.
Table 4 displays associations of patient characteristics with switching among those who
failed according to their site’s failure definition. In a multivariable analysis, CD4 count at
failure was weakly associated with switching. Those with a higher rate of decline in CD4
count since failure were however more likely to switch. A CD4 % drop of −100% to −51%
vs. remaining relatively stable (−25% to 25%) was associated with a two-fold increased
switch rate (aHR: 1.82; 95%CI:1.24–2.68) while a CD4 % drop of −50% to 0% compared to
remaining stable (−25% to 25%) was associated with a 1.3-fold increased switch rate
(95%CI:0.93–1.77). There remained a two-fold difference between the cohorts with the
fastest and slowest times to switching in virologically failing patients.
DISCUSSION
In one of the largest studies to date from the South African national treatment programme
exploring the extent of virologic treatment failure, we found 8–17% of patients failed first-
line therapy by five years on treatment using survival analysis depending on the definition of
confirmed failure used, in line with findings from individual cohorts.6,31 There were
expected delays both between a first elevated viral load and confirmation of treatment
failure, and subsequent switching of therapy in those who switched (median of 2.7 and 4.6
months respectively). While nearly three-quarters of patients with confirmed virologic
failure and at least six months of additional follow-up had switched, there was up to a two-
fold difference in time to switching between cohorts, with switching occurring faster in
patients with rapidly falling CD4 counts.
Definition of virologic failure
South African and WHO guidelines suggest a pragmatic approach to defining virologic
treatment failure which relies on confirmation of viraemia after attempts to optimize
adherence. The World Health Organization 2010 guideline revisions recommend that when
viral load monitoring is available, “A persistent viral load of >5000 copies/ml confirms
treatment failure.”1 South African guidelines in operation at the time of this study used the
same confirmatory threshold, but allowed for the first elevation to be above 400 copies/ml.
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The approach has been shown to successfully select out patients with high levels of
resistance warranting switching to second-line therapy, but low levels of cross-resistance
between first and second-line regimens.32 As evidenced by this study however, the exact
interpretation of this approach is varied and can profoundly impact the number of patients
who meet the failure definition and require second-line therapy.
Three subsequent guideline changes in South Africa may impact the interpretation of these
findings.28 In April 2010 the initial recommended NRTI backbone was changed from
stavudine and lamivudine to tenofovir and lamivudine, while routine viral load testing
frequency was dropped from six-monthly to annually beyond the first year on ART. The
threshold for confirming virologic failure was lowered from 5,000 to 1,000 copies/ml with
the confirmatory test now required within three months of the initial elevation.
Whereas the less frequent monitoring may increase delays to identifying patients failing
virologically, with the introduction of tenofovir there may also now be fewer concerns about
the accumulation of thymidine analogue mutations while viraemic, with the associated
potential to compromise second-line therapy.
Switching of failing patients
A previous analysis from the IeDEA collaboration demonstrated switching occurred more
frequently and at higher CD4 counts in sites with viral load monitoring.33 Mortality was
lower and CD4 trajectories steeper in viral load sites,12,34 though this has not been
consistent across studies.35 The current study provides further insight into the period
between virologic failure confirmation and switching. A high proportion of patients who
should be switched are switched, and compliance with guideline advice is more complete
than is the case for children in South Africa.36 Nevertheless, the median delay of nearly 5
months between confirmation of failure and switch combined with inter-cohort differences,
suggests that administrative and clinical factors are additionally impacting on compliance
with switching guidelines. The strong association between CD4 count trajectory and
switching further suggests that clinical judgment is a contributor to this variability.
Current data suggest PI-based second-line therapy is not being compromised by delays in
switching resulting from South Africa’s pragmatic virologic failure guidelines, with the
majority of patients failing second-line therapy remaining susceptible to boosted
lopinavir.37,38 The finding that most early failures on second-line are adherence-related
supports the provision for a period of active adherence optimization prior to switching.
Delays in switching on the other hand place patients at increased risk of illness and death
through longer durations spent viraemic and at lower CD4 counts.12,13 An important follow-
on analysis will therefore be to estimate the causal effect of delays in switching patients with
confirmed virologic failing.39
Associations with failure
The associations with virologic failure we found mirror those found in individual cohorts.
Measures of advanced disease (CD4 count, WHO stage, viral load) were associated with
failure. We found a strong association with treatment interruptions, perhaps serving both as
a proxy for poor adherence and as a consequence of the long half-life of NNRTIs which
remain in circulation longer than the other drugs following unplanned interruptions.40,41 We
again found NVP as choice of NNRTI was associated with virologic failure, a consistent
finding across observational studies from different settings,31,42–44 and is not in conflict
with the clinical trial data for African sites.45,46
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Limitations
Our study has several limitations. First we lacked good PMTCT data to be able to examine
the role of single-dose NVP exposure in treatment failure. Second, confounding by
indication could have occurred, particularly in the relationship between nevirapine use and
failure in sites where efavirenz was more commonly used. Next, although we observed
modest differences between cohorts in the completion and frequency of viral load testing,
failure to test or report viral load results according to guidelines would reduce the
probability of meeting failure definitions. We also found the overall failure rate was
sensitive to assumptions made about whether patients with only a single detectable viral load
before death were truly failures. Also differences in how failure was defined by each cohort
could have led to underestimates of failure rates using definitions with higher thresholds if
patients with detectable viral loads below the threshold were switched before they could
reach a higher threshold. Differences in follow-up time between cohorts may also explain
some of the differences in failure rates observed. Finally, we had no data on two important
potential predictors of treatment failure, adherence47 and prior resistance.
In conclusion, future treatment guidelines revisions should make explicit the rationale for
the thresholds chosen to define and confirm virologic failure in light of our finding that these
profoundly on the proportion of patients who meet failure definitions, and resultant costs of
second-line treatment. Although guidance on switching failing patients is generally
followed, there remains considerable variability in time to switching after failure, due to
both clinician and administrative factors. Future studies should investigate the impact failure
definitions and delays in switching have on subsequent treatment outcomes.
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Figure 1.
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Appendix 1.
Study Profile of Virologic Treatment Failure and Switching to Second-line Antiretroviral
Therapy in the IeDEA-SA South Africa Cohort
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Appendix 2.
Kaplan-Meier Curves of predictors of failure stratified by a) cohort, b) CD4 count at ART
initiation, c) viral load at ART initiation, and d) gaps in treatment
Log-rank p-value for cohort (p<0.0001), CD4 count at ART initiation (p<0.0001), viral load
at ART initiation (p=0.0011), and gaps in treatment (p<0.0001)
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Table 2
Characteristics of eligible patients participating in South African Cohorts in the IeDEA-SA network
Patient characteristic Exposure Full cohort¥
Treatment provider Themba Lethu 8157 (41.5%)
Gugulethu 2210 (11.2%)
Khayelitsha 6220 (31.7%)
McCord 2102 (10.7%)
Tygerberg 956 (4.9%)
Gender
Male 6665 (33.9%)
Female 12980 (66.1%)
Age at ART initiation
<20 137 (0.7%)
20 – 29 5190 (26.4%)
30 – 39 9046 (46.0%)
40 – 49 4005 (20.4%)
50+ 1267 (6.4%)
Year of ART initiation
< 2004 925 (4.7%)
2004 3345 (17.0%)
2005 5137 (26.1%)
2006 5743 (29.2%)
2007 3812 (19.4%)
2008+ 683 (3.5%)
First ART
D4T-3TC-EFV 13425 (68.3%)
AZT-3TC-EFV 977 (5.0%)
D4T-3TC-NVP 4190 (21.3%)
AZT-3TC-NVP 1053 (5.4%)
WHO stage at ART initiation
Stage I 5296 (30.6%)
Stage II 1230 (7.1%)
Stage III 7261 (42.0%)
Stage IV 3521 (20.3%)
Missing 2337
Patient on TB treatment at start of HAART?
No 8651 (63.9%)
Yes 4893 (36.1%)
Missing 6101
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Patient characteristic Exposure Full cohort¥
Exposed to PMTCT
No 3745 (34.3%)
Yes 499 (4.6%)
N/A 6665 (61.1%)
Missing 8736
Pregnant at start of HAART?
Yes 510 (3.9%)
No 5798 (44.7%)
NA 6665 (51.4%)
Missing 7072
CD4 count at ART initiation (cells/mm3)
<25 3172 (17.5%)
25–49 2341 (12.9%)
50–99 4061 (22.4%)
100–199 7193 (39.6%)
200–349 1194 (6.6%)
>350 187 (1.0%)
Missing 1497
Median (IQR)CD4 at ART initiation 93 (39–155)
Viral load at ART initiation
>1,000,000 372 (4.7%)
100,000–1,000,000 2748 (34.9%)
10,000–100,000 3672 (46.6%)
< 10,000 1093 (13.9%)
Missing 11760
Viral load at ART initiation ×1000 (Median (IQR)) Drug interruptions of 7+ days 65 (20–220)
0 18732 (95.4%)
1 885 (4.5%)
2+ 28 (0.1%)
Outcome
Alive 15362 (79.0%)
Died 921 (4.7%)
LTFU 1834 (9.4%)
Transferred 1339 (6.9%)
Median (IQR) weight at ART initiation (kgs) [number of measurements] 59 (52–67) [14120]
¥Percentages are column percentages
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Table 3
Predictors of first-line antiretroviral virologic treatment failure in the IeDEA-SA cohorts in South Africa
Group Rate/100py (N/p-years) Crude Model Adjusted Model Adjusted Model with Multiple Imputation
Treatment Provider N=19645 N=19645
 Themba Lethu 3.46 (583/16871) Reference Reference Reference
 Gugulethu 3.35 (155/4628) 0.96 (0.80–1.15) 0.73 (0.56–0.95) 0.73 (0.57 – 0.93)
 Khayelitsha 3.90 (479/12269) 1.15 (1.02–1.30) 0.82 (0.67–1.00) 0.83 (0.63 – 1.10)
 McCord 1.24 (47/3798) 0.37 (0.27–0.50) 0.29 (0.16–0.53) 0.25 (0.17 – 0.37)
 Tygerberg 4.58 (84/1834) 1.31 (1.04–1.65) 0.86 (0.62–1.20) 0.85 (0.66 – 1.10)
Age
 10 year increase N/A 0.73 (0.68–0.78) 0.73 (0.68–0.79) 0.73 (0.68 – 0.79)
Gender
 Male 3.34 (434/12986) Reference Reference Reference
 Female 3.46 (914/26414) 1.02 (0.91–1.14) 0.95 (0.81–1.12) 0.86 (0.76 – 0.97)
Year of initiation of 1st line ART
 < 2004 3.92 (148/3776) Reference Reference Reference
 2004 3.54 (357/10084) 0.82 (0.67–1.00) 0.88 (0.72–1.08) 0.88 (0.72 – 1.08)
 2005 3.84 (459/11967) 0.86 (0.71–1.04) 0.97 (0.79–1.19) 0.99 (0.81 – 1.21)
 2006 3.43 (316/9203) 0.86 (0.70–1.06) 0.96 (0.77–1.20) 0.98 (0.78 – 1.22)
 2007+ 1.56 (68/4370) 0.64 (0.47–0.86) 0.72 (0.52–1.00) 0.78 (0.56 – 1.07)
NNRTI in first-line ART regimen
 EFV 3.07 (897/29177) Reference Reference Reference
 NVP 4.41 (451/10224) 1.46 (1.30–1.64) 1.45 (1.26–1.66) 1.48 (1.29–1.71)
TB treatment at ART Start
 No 3.50 (631/18024) Reference Reference Reference
 Yes 2.85 (258/9068) 0.83 (0.72–0.96) 1.11 (0.93–1.32) 1.11 (0.93–1.32)
 Missing 3.73 (459/12308) 1.06 (0.94–1.20) 1.26 (1.00–1.59) N/A
CD4 count at ART initiation (cells/mm3)
 0–24 4.63 (300/6478) 1.63 (1.40–1.89) 1.60 (1.37–1.87) 1.62 (1.40–1.87)
 25–49 3.51 (169/4812) 1.24 (1.04–1.48) 1.21 (1.01–1.45) 1.24 (1.03–1.51)
 50–99 3.78 (318/8410) 1.32 (1.14–1.53) 1.29 (1.11–1.50) 1.31 (1.13–1.51)
 100–199 2.84 (402/14134) Reference Reference Reference
 200–349 2.46 (52/2113) 0.90 (0.67–1.20) 0.91 (0.68–1.22) 0.89 (0.67–1.19)
 >350 1.20 (4/332) 0.45 (0.17–1.20) 0.47 (0.17–1.27) 0.45 (0.17–1.21)
 Missing 3.30 (103/3121) 1.21 (0.97–1.50) 1.15 (0.92–1.44) N/A
Viral Load at ART initiation
 <10,000 2.88 (61/2120) Reference Reference Reference
 10,000–99,999 3.81 (283/7422) 1.29 (0.98–1.70) 1.10 (0.83–1.46) 1.14 (0.92–1.41)
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Group Rate/100py (N/p-years) Crude Model Adjusted Model Adjusted Model with Multiple Imputation
 100,000–999,999 4.48 (289/6449) 1.47 (1.12–1.94) 1.20 (0.90–1.60) 1.33 (1.10–1.61)
 ≥ 1,000,000 4.73 (42/888) 1.53 (1.03–2.27) 1.19 (0.79–1.79) 1.40 (1.01–1.95)
 Missing 2.99 (673/22521) 1.05 (0.81–1.36) 0.98 (0.74–1.29) N/A
WHO Stage at ART initiation
 I/II 2.96 (384/12995) Reference Reference Reference
 III/IV 4.04 (896/22175) 1.35 (1.20–1.52) 1.28 (1.12–1.47) 1.36 (1.08–1.72)
 Missing 1.61 (68/4231) 0.55 (0.42–0.71) 1.40 (0.84–2.32) N/A
ART treatment interruptions of >7days
 0 3.02 (1000/37045) Reference Reference Reference
 1 9.02 (202/2239) 2.36 (2.03–2.75) 2.46 (2.11–2.87) 2.49 (2.13–2.91)
 2+ 24.17 (28/116) 6.74 (4.62–9.83) 7.25 (4.95–10.62) 7.22 (4.93–10.6)
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Table 4
Predictors of Switch among those who Failed
Predictor Crude Model N=893 Adjusted Model N=893
Treatment provider
 Themba Lethu Reference Reference
 Gugulethu 0.62 (0.49–0.79) 0.61 (0.48–0.78)
 Khayelitsha 0.54 (0.45–0.65) 0.51 (0.40–0.65)
 McCord 0.97 (0.52–1.82) 0.91 (0.48–1.73)
 Tygerberg 1.07 (0.74–1.55) 1.08 (0.73–1.61)
Age
 10 year increase 1.03 (0.94–1.13) 0.96 (0.87–1.06)
Gender
 Male Reference Reference
 Female 0.94 (0.80–1.10) 0.96 (0.81–1.14)
Year failed first-line ART
 < 2004 Reference Reference
 2004 0.91 (0.53–1.56) 0.93 (0.54–1.61)
 2005 0.99 (0.66–1.48) 0.77 (0.51–1.17)
 2006 0.93 (0.64–1.36) 0.61 (0.40–0.93)
 2007+ 1.50 (1.03–2.19) 0.97 (0.63–1.49)
Years on ART at failure
 < 1 Reference Reference
 1–1.9 0.97 (0.82–1.15) 0.99 (0.83–1.19)
 2–2. 1.23 (0.96–1.57) 1.09 (0.84–1.41)
 3–3.9 0.92 (0.61–1.39) 0.91 (0.59–1.40)
 4+ 1.26 (0.56–2.84) 1.65 (0.72–3.76)
Current CD4 (cells/mm3)
 350+ Reference Reference
 200–349 1.19 (0.94–1.51) 1.02 (0.79–1.31)
 100–199 1.27 (0.99–1.62) 1.04 (0.80–1.35)
 50–99 1.47 (1.09–1.99) 1.18 (0.85–1.64)
 0–49 1.57 (1.14–2.16) 1.01 (0.70–1.46)
% CD4 change from failure
 −100% to −51% 1.72 (1.22–2.42) 1.82 (1.24–2.68)
 −50% to −26% 1.11 (0.81–1.52) 1.28 (0.93–1.77)
 −25% to 25% Reference Reference
 >25% 0.54 (0.41–0.70) 0.50 (0.38–0.66)
 Missing 0.50 (0.28–0.89) 0.59 (0.32–1.09)
Viral load at failure
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Predictor Crude Model N=893 Adjusted Model N=893
 <10,000 Reference Reference
 10,000–99,999 1.12 (0.96–1.31) 1.15 (0.97–1.36)
 100,000–999,999 0.61 (0.42–0.89) 0.84 (0.56–1.27)
 ≥ 1,000,000 3.14 (0.78–12.64) 1.92 (0.45–8.21)
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